ARTICLE | Company News
AlphaRx, Riso Pharma Tech deal
October 5, 2009 7:00 AM UTC
AlphaRx granted Riso exclusive, worldwide rights to develop and commercialize ARX606T, excluding Asia. The topical formulation of an undisclosed growth factor is in preclinical development for wound h...